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We describe a novel inhibitor of angiogenesis, Irsogladine, an anti-ulcer drug. Irsogladine inhibited plasminogen activator synthesis of, and tube 
formation by, human microvascular endothelial cells in type 1 collagen gel treated with an angiogenic growth factor, EGF. Furthermore, Irsogladine 
administered orally significantly inhibited in vivo angiogenesis in mice. Irsogladine may be useful in the treatment of diseases associated with 
angiogenesis. 
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1. INTRODUCTION 
Angiogenesis participates in many pathological states 
such as growth of various tumors, diabetic retinopathy, 
and arthritis. Therefore, inhibitors of angiogenesis may 
be useful for the treatment of such diseases. To obtain 
an effective agent for the treatment of angiogenesis, it 
is inevitable to understand the cellular and molecular 
mechanisms of angiogenesis. Growth factors are 
thought to play an important role in angiogenesis (re- 
viewed in [l]). We previously observed that the induc- 
tion of tissue-type plasminogen activator (tPA) in 
human microvascular endothelial cells is indispensable 
for growth factor-dependent angiogenesis in vitro [2]. 
Therefore, we examined the ability of substances to in- 
hibit the induction of PA synthesis in growth factor- 
treated endothelial cells. Here, we describe that 
Irsogladine, an anti-ulcer drug, inhibited the induction 
of PA synthesis in endothelial cells as well as in vitro 
and in vivo angiogenesis. 
2. MATERIALS AND METHODS 
2.1. Cells 
Human omental microvascular endothelial (HOME) cells were iso- 
lated from omental adipose tissue and were grown in Medium 199 
(M-199) containing 10% fetal bovine serum (FBS), as described previ- 
ously [3]. 
2.2. Materials 
Epidermal growth factor (EGF) was purchased from Toyobo Co. 
(Osaka, Japan). IrsogIadine was obtained from the Research Labora- 
tories of Nippon Shinyaku Co. (Kyoto, Japan). Human tPA cDNA 
was obtained from Dr. W.-D. Schleuning (Schering Akiengesellschaft 
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Pharma Forschung, Berlin, Germany) [4]. Plasminogen activator in- 
hibitor 1 (PAI-1) cDNA was obtained from Dr. D.J. Loskutoff (Re- 
search Institute of Scripps Clinic, La Jolla, CA) [5]. 
2.3. Northern blot analysis 
Northern blot analysis was undertaken as described previously [2,6]. 
HOME cells were incubated in M-199 containing 1% FBS with or 
without EGF (10 ng/mI) and/or Irsogladine (10m4 M) for 12 h. Total 
RNA was extracted, fractionated on 1% agarose gels containing 2.2 
M formaldehyde, and transferred to a Nytran filter (Schleicher & 
Schuell). Northern blots were probed with tPA and PAI- cDNAs. 
2.4. Tube formation by HOME cells 
Tube formation by HOME cells was examined as previously de- 
scribed [2]. Briefly, HOME cells were grown on the surface of type 1 
collagen gels (Nitta Gelatin, Osaka, Japan). When the cells became 
confluent, the medium was replaced by M-199 containing 1% FBS 
with or without EGF (10 &ml) and/or Irsogladine (10m4 M). After 
a 3 day incubation, tube-like structures in the gels were quantified by 
a Cosmozone 1 S Image Analyzer (Nikon, Tokyo, Japan). Eight ran- 
dom fields were measured and the total tube length per field ( x 200 
magnification) was determined. 
2.5. A mouse dorsal air sac method 
In vivo angiogenesis was observed by using a mouse dorsal air sac 
method as described elsewhere [7]. Briefly, angiogenesis-inducing cells 
were suspended in phosphate-buffered saline (PBS) at a concentration 
of 5 x 10’ cells/ml. The cell suspension (0.2 ml) was injected into a 
chamber consisting of a Milhpore ring (Millipore Co., MA) and mi- 
cropore filters (0.22 pm pore size, Millipore, Co., MA) on both sides 
of the ring. The chamber containing angiogenesis-inducing cells or 10 
mg/ml of bovine serum albumin (BSA) was implanted into a dorsal 
air sac of a 5-7-week-old male ICR mouse. Irsogladine (30, 100, and 
300 mg/kg) was given orally twice a day. Mice were killed and carefully 
skinned on the third day after the implantation. 
3. RESULTS AND DISCUSSION 
The structure of Irsogladine is shown in Fig. 1. The 
molecular weight of Irsogladine is 372.17 Da. We exam- 
ined the effect of Irsogladine on the induction of tPA 
mRNA in growth factor-treated HOME cells. As shown 
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Fig. 1. The structure of Irsogladine. 
in Fig. 2, EGF (10 &ml) induced the expression of 
both tPA and PAI- mRNA in HOME cells at a level 
similar to that previously reported [2,8]. Irsogladine 
(1 0m4 M) alone did not affect the basal expression of tPA 
or PAI- mRNA in HOME cells, however, simultane- 
ous addition of Irsogladine markedly inhibited the 
EGF-induced tPA expression but not PAI- expression 
in HOME cells. Thus, Irsogladine was nominated as a 
candidate for the inhibitor of angiogenesis. Next, we 
examined whether Irsogladine blocked tube formation 
by EGF-treated HOME cells in type 1 collagen gels. As 
shown in Fig. 3, EGF (10 rig/ml) induced tube forma- 
tion by HOME cells in the gel after a 3-day incubation 
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Fig. 2. Northern blot analysis of tPA and PAL1 mRNA in HOME 
cells. HOME cells were incubated with 10 ng/ml of EGF and/or 10e4 
M Irsogladine for 12 h. After the incubation, total RNA was extracted 
and Northern blot analysis of tPA and PAI-I was carried out, as 
described in section 2. 
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Fig. 3. Effect of Irsogladine on tube formation by EGF-treated 
HOME cells in type 1 collagen gel. HOME cells on type 1 collagen gel 
were treated with 10 ng/ml of EGF and/or lO-4 M or Irsogladine. After 
a 3-day incubation, the total length of tube-like structures per field in 
the gel was determined, using a Cosmozone 1s Image Analyzer, as 
described in section 2. Values represent mean + S.D. 
as was reported previously [2,3]. While Irsogladine (1 0e4 
M) alone has no effect on tube formation by HOME 
cells, simultaneous addition of Irsogladine almost com- 
pletely blocked the stimulatory effect of EGF on tube 
formation in the gel. We further examined whether the 
anti-angiogenic effect of Irsogladine could be repro- 
duced on the in vivo system. We used a mouse dorsal 
air sac method as an in vivo model of angiogenesis. 
Various cells types, including Sarcoma 180, B16 mela- 
noma cell lines, as well as HOME cells, were applied to 
this system as angiogenesis-inducing cells, and HOME 
cells were found to be stable and have the highest angi- 
ogenic potential. Therefore, we chose a HOME cell as 
an angiogenesis nducer. As shown in Fig. 4, the implan- 
tation of the chamber containing BSA did not cause any 
angiogenesis, indicating that the mechanical maneuver 
itself did not cause angiogenesis. The chamber contain- 
ing HOME cells induced marked angiogenesis on the 
third day after the implantation, however, Irsogladine 
given orally twice daily inhibited the induction of angi- 
ogenesis by HOME cells. The inhibitory effect of 
Irsogladine was dose dependent, and 300 mglkg of 
Irsogladine twice daily significantly inhibited angio- 
genesis. The mice looked healthy during the experiment, 
and did not show any signs of toxic effects or reduction 
of body weight by the treatment with Irsogladine (data 
not shown). 
Angiogenesis is a complex phenomenon which in- 
cludes at least four sequential steps: degradation of vas- 
cular basement membrane and interstitial matrices by 
endothelial cells; migration of endothelial cells; prolifer- 
ation of endothelial cells; and formation of capillary 
loops by endothelial cells (reviewed in [9]). A cascade of 
proteinases is required for the degradation of extracellu- 
lar matrices. PAS convert plasminogen to plasmin. 
While plasmin itself is reponsible for the degradation of 
extracellular matrices, plasmin also converts pro-metal- 
loproteinase to an active form. Endothelial cells have 
the ability to produce PAS and pro-metalloproteinase, 
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Fig. 4. Effect of Irsogladine on angiogenesis in mice. The Millipore chamber containing HOME cells or BSA was implanted into a mouse dorsal 
air sac. Irsogladine at a dose of 30, 100, and 300 mg/kg was administered orally to mice twice daily. Mice were killed and skinned 3 days after 
the implantation as described in section 2. 
and thus the induction of PAS in endothelial cells is 
proposed as a key event for the initiation of angiogene- 
sis (reviewed in [lO,l 11. We have previously observed 
that the induction of tissue-type PA (tPA) is indispensa- 
ble for growth factor-dependent angiogenesis in vitro 
[2]. A growth factor-like EGF or transforming growth 
factor a (TGFa) stimulates tPA synthesis, as well as 
migration and proliferation of HOME cells [ 12,131, and 
induces tube formation in type 1 collagen gel [2,8]. The 
elimination of tPA activity by anti-tPA antibody or 
serine protease inhibitors inhibited the growth factor- 
induced tube formation in vitro [2], however, the sys- 
temic administration of serine protease inhibitors was 
not effective for the inhibition of angiogenesis in vivo 
(data not shown). Therefore, we screened several sub- 
stances and found that Irsogladine, an anti-ulcer drug, 
could block the induction of tPA mRNA in, and tube 
formation by, EGF-treated HOME cells. We further 
confirmed the anti-angiogenic effect of Irsogladine by 
an in vivo assay system using a mouse dorsal air sac 
method. We chose a HOME cell as an angiogenesis- 
inducing cell for our in vivo system. Although the re- 
sponsible factor(s) for angiogenesis induced by HOME 
cells was obscure, we observed that HOME cells pro- 
duced basic fibroblast growth factor (bFGF), a potent 
angiogenic growth factor, but not EGF nor TGFa [6]. 
Therefore, the angiogenic potential of HOME cells is 
not related to either EGF or TGFa, and an anti-angio- 
genie effect of Irsogladine may be general and not re- 
stricted to the effect of EGF. 
The mechanism by which Irsogladine eliminates the 
induction of tPA in growth factor-treated HOME cells 
is currently obscure. Migrating endothelial cells express 
PA activity [ 14,151, while Gap-junctional communica- 
tion increases during the migration of endothelial cells 
[16,17]. These findings suggest a possible relationship 
between Gap-junctional communication and PA activ- 
ity of endothelial cells. Irsogladine has been recently 
shown to modulate Gap-junctional intercellular com- 
munication [18]. Thus, Irsogladine may abrogate the 
induction of PA by modulating Gap-junctional commu- 
nication of endothelial cells. Further study is currently 
underway to clarify the mode of action of Irsogladine 
on endothelial cells. Finally, since Irsogladine is innocu- 
ous and has been in clinical use in Japan, it can be a 
potential candidate for the treatment of diseases associ- 
ated with angiogenesis. 
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